APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Growth and Trends Forecast to 2032

Report ID 174045080131 December 2025100 pages

Choose your research edition.

Industry ResearchVancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections include Eli Lily, Wockhardt Ltd, Therapeutic Systems Research Laboratories Inc, TGV-Inhalonix Inc, Roivant Sciences Ltd, Lysimmune BioScience, Destiny Pharma Plc, Debiopharm International SA and CrystalGenomics Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market by Company

Eli Lily

Wockhardt Ltd

Therapeutic Systems Research Laboratories Inc

TGV-Inhalonix Inc

Roivant Sciences Ltd

Lysimmune BioScience

Destiny Pharma Plc

Debiopharm International SA

CrystalGenomics Inc

Amprologix Ltd

Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Segment by Type

Injection

Pills

Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Segment by Application

Hospital

Clinic

Other

Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Injection Table 2. Major Company of Pills Table 3. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021-2026) & (K Units) Table 5. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Volume by Type (2021-2026) Table 6. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021-2026) & (US$ Million) Table 7. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Value by Type (2021-2026) Table 8. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Type (2021-2026) & (US$/Unit) Table 9. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2027-2032) & (K Units) Table 10. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Volume by Type (2027-2032) Table 11. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2027-2032) & (US$ Million) Table 12. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Value by Type (2027-2032) Table 13. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Type (2027-2032) & (US$/Unit) Table 14. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021-2026) & (K Units) Table 15. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021-2026) & (K Units) Table 17. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021-2026) & (K Units) Table 21. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021-2026) & (US$ Million) Table 24. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Trends Table 25. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Drivers Table 26. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Opportunities and Challenges Table 27. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Restraints Table 28. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Company (2021-2026) Table 30. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Company (2021-2026) & (K Units) Table 31. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Share by Company (2021-2026) Table 32. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Major Company Production Sites and Headquarters Table 35. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Company, Product Type & Application Table 36. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Region (2021-2026) & (K Units) Table 41. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Volume by Region (2021-2026) Table 42. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Region (2021-2026) & (US$ Million) Table 43. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Value by Region (2021-2026) Table 44. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Region (2027-2032) & (K Units) Table 46. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Volume by Region (2027-2032) Table 47. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Region (2027-2032) & (US$ Million) Table 48. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Value by Region (2027-2032) Table 49. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021-2026) & (K Units) Table 52. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Volume by Application (2021-2026) Table 53. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021-2026) & (US$ Million) Table 54. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Value by Application (2021-2026) Table 55. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Application (2021-2026) & (US$/Unit) Table 56. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2027-2032) & (K Units) Table 57. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Volume by Application (2027-2032) Table 58. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2027-2032) & (US$ Million) Table 59. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Value by Application (2027-2032) Table 60. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Application (2027-2032) & (US$/Unit) Table 61. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021-2026) & (K Units) Table 62. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021-2026) & (K Units) Table 64. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021-2026) & (K Units) Table 68. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021-2026) & (US$ Million) Table 71. Eli Lily Company Information Table 72. Eli Lily Business Overview Table 73. Eli Lily Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Eli Lily Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio Table 75. Eli Lily Recent Development Table 76. Wockhardt Ltd Company Information Table 77. Wockhardt Ltd Business Overview Table 78. Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio Table 80. Wockhardt Ltd Recent Development Table 81. Therapeutic Systems Research Laboratories Inc Company Information Table 82. Therapeutic Systems Research Laboratories Inc Business Overview Table 83. Therapeutic Systems Research Laboratories Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Therapeutic Systems Research Laboratories Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio Table 85. Therapeutic Systems Research Laboratories Inc Recent Development Table 86. TGV-Inhalonix Inc Company Information Table 87. TGV-Inhalonix Inc Business Overview Table 88. TGV-Inhalonix Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. TGV-Inhalonix Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio Table 90. TGV-Inhalonix Inc Recent Development Table 91. Roivant Sciences Ltd Company Information Table 92. Roivant Sciences Ltd Business Overview Table 93. Roivant Sciences Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Roivant Sciences Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio Table 95. Roivant Sciences Ltd Recent Development Table 96. Lysimmune BioScience Company Information Table 97. Lysimmune BioScience Business Overview Table 98. Lysimmune BioScience Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Lysimmune BioScience Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio Table 100. Lysimmune BioScience Recent Development Table 101. Destiny Pharma Plc Company Information Table 102. Destiny Pharma Plc Business Overview Table 103. Destiny Pharma Plc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Destiny Pharma Plc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio Table 105. Destiny Pharma Plc Recent Development Table 106. Debiopharm International SA Company Information Table 107. Debiopharm International SA Business Overview Table 108. Debiopharm International SA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Debiopharm International SA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio Table 110. Debiopharm International SA Recent Development Table 111. CrystalGenomics Inc Company Information Table 112. CrystalGenomics Inc Business Overview Table 113. CrystalGenomics Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. CrystalGenomics Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio Table 115. CrystalGenomics Inc Recent Development Table 116. Amprologix Ltd Company Information Table 117. Amprologix Ltd Business Overview Table 118. Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio Table 120. Amprologix Ltd Recent Development Table 121. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 122. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021-2026) & (K Units) Table 123. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Country (2021-2026) Table 124. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Forecast by Country (2027-2032) & (K Units) Table 125. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share Forecast by Country (2027-2032) Table 126. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 127. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2021-2026) & (US$ Million) Table 128. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Country (2021-2026) Table 129. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Forecast by Country (2027-2032) & (US$ Million) Table 130. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share Forecast by Country (2027-2032) Table 131. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 132. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021-2026) & (K Units) Table 133. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Country (2021-2026) Table 134. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Forecast by Country (2027-2032) & (K Units) Table 135. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share Forecast by Country (2027-2032) Table 136. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 137. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2021-2026) & (US$ Million) Table 138. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Country (2021-2026) Table 139. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Forecast by Country (2027-2032) & (US$ Million) Table 140. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share Forecast by Country (2027-2032) Table 141. Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 142. Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021-2026) & (K Units) Table 143. Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Country (2021-2026) Table 144. Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Forecast by Country (2027-2032) & (K Units) Table 145. Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share Forecast by Country (2027-2032) Table 146. Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2021-2026) & (US$ Million) Table 148. Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Country (2021-2026) Table 149. Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share Forecast by Country (2027-2032) Table 151. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 152. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021-2026) & (K Units) Table 153. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Country (2021-2026) Table 154. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Forecast by Country (2027-2032) & (K Units) Table 155. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share Forecast by Country (2027-2032) Table 156. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2021-2026) & (US$ Million) Table 158. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Country (2021-2026) Table 159. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share Forecast by Country (2027-2032) Table 161. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 162. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021-2026) & (K Units) Table 163. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Country (2021-2026) Table 164. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Forecast by Country (2027-2032) & (K Units) Table 165. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share Forecast by Country (2027-2032) Table 166. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2021-2026) & (US$ Million) Table 168. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Country (2021-2026) Table 169. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share Forecast by Country (2027-2032) Table 171. Key Raw Materials Table 172. Raw Materials Key Suppliers Table 173. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Distributors List Table 174. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Customers List Table 175. Research Programs/Design for This Report Table 176. Authors List of This Report Table 177. Secondary Sources Table 178. Primary Sources List of Figures Figure 1. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Image Figure 2. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size (2021-2032) & (US$ Million) Figure 4. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (2021-2032) & (K Units) Figure 5. Injection Image Figure 6. Global Injection Sales YoY Growth (2021-2032) & (K Units) Figure 7. Pills Image Figure 8. Global Pills Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Type 2025 VS 2032 Figure 11. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Volume by Type in 2025 Figure 12. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Value by Type in 2025 Figure 13. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Volume by Type in 2025 Figure 14. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Value by Type in 2025 Figure 17. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hospital Image Figure 24. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 25. Clinic Image Figure 26. Global Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 27. Other Image Figure 28. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 29. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Application 2025 VS 2032 Figure 31. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Volume by Application in 2025 Figure 32. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Value by Application in 2025 Figure 33. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Volume by Application in 2025 Figure 34. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Value by Application in 2025 Figure 37. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share in Value by Application in 2025 Figure 41. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Injection
  • Pills
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Eli Lily
  • Wockhardt Ltd
  • Therapeutic Systems Research Laboratories Inc
  • TGV-Inhalonix Inc
  • Roivant Sciences Ltd
  • Lysimmune BioScience
  • Destiny Pharma Plc
  • Debiopharm International SA
  • CrystalGenomics Inc
  • Amprologix Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market by Type
  6. 1.3.1 Injection
  7. 1.3.2 Pills
  8. 1.4 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type
  9. 1.4.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Trends
  2. 2.2 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Drivers
  3. 2.3 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Opportunities and Challenges
  4. 2.4 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (2021-2026)
  2. 3.2 Global Top Players by Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (2021-2026)
  3. 3.3 Global Top Players by Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price (2021-2026)
  4. 3.4 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Major Company Production Sites & Headquarters
  6. 3.6 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Company, Product Type & Application
  7. 3.7 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Tier 1, Tier 2, and Tier 3
4 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Regional Status and Outlook
  1. 4.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Historic Market Size by Region
  3. 4.2.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Forecasted Market Size by Region
  7. 4.3.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections by Application
  1. 5.1 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application
  6. 5.2.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Eli Lily
  2. 6.1.1 Eli Lily Company Information
  3. 6.1.2 Eli Lily Business Overview
  4. 6.1.3 Eli Lily Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Eli Lily Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio
  6. 6.1.5 Eli Lily Recent Developments
  7. 6.2 Wockhardt Ltd
  8. 6.2.1 Wockhardt Ltd Company Information
  9. 6.2.2 Wockhardt Ltd Business Overview
  10. 6.2.3 Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio
  12. 6.2.5 Wockhardt Ltd Recent Developments
  13. 6.3 Therapeutic Systems Research Laboratories Inc
  14. 6.3.1 Therapeutic Systems Research Laboratories Inc Company Information
  15. 6.3.2 Therapeutic Systems Research Laboratories Inc Business Overview
  16. 6.3.3 Therapeutic Systems Research Laboratories Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Therapeutic Systems Research Laboratories Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio
  18. 6.3.5 Therapeutic Systems Research Laboratories Inc Recent Developments
  19. 6.4 TGV-Inhalonix Inc
  20. 6.4.1 TGV-Inhalonix Inc Company Information
  21. 6.4.2 TGV-Inhalonix Inc Business Overview
  22. 6.4.3 TGV-Inhalonix Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 TGV-Inhalonix Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio
  24. 6.4.5 TGV-Inhalonix Inc Recent Developments
  25. 6.5 Roivant Sciences Ltd
  26. 6.5.1 Roivant Sciences Ltd Company Information
  27. 6.5.2 Roivant Sciences Ltd Business Overview
  28. 6.5.3 Roivant Sciences Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Roivant Sciences Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio
  30. 6.5.5 Roivant Sciences Ltd Recent Developments
  31. 6.6 Lysimmune BioScience
  32. 6.6.1 Lysimmune BioScience Company Information
  33. 6.6.2 Lysimmune BioScience Business Overview
  34. 6.6.3 Lysimmune BioScience Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Lysimmune BioScience Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio
  36. 6.6.5 Lysimmune BioScience Recent Developments
  37. 6.7 Destiny Pharma Plc
  38. 6.7.1 Destiny Pharma Plc Company Information
  39. 6.7.2 Destiny Pharma Plc Business Overview
  40. 6.7.3 Destiny Pharma Plc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Destiny Pharma Plc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio
  42. 6.7.5 Destiny Pharma Plc Recent Developments
  43. 6.8 Debiopharm International SA
  44. 6.8.1 Debiopharm International SA Company Information
  45. 6.8.2 Debiopharm International SA Business Overview
  46. 6.8.3 Debiopharm International SA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Debiopharm International SA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio
  48. 6.8.5 Debiopharm International SA Recent Developments
  49. 6.9 CrystalGenomics Inc
  50. 6.9.1 CrystalGenomics Inc Company Information
  51. 6.9.2 CrystalGenomics Inc Business Overview
  52. 6.9.3 CrystalGenomics Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 CrystalGenomics Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio
  54. 6.9.5 CrystalGenomics Inc Recent Developments
  55. 6.10 Amprologix Ltd
  56. 6.10.1 Amprologix Ltd Company Information
  57. 6.10.2 Amprologix Ltd Business Overview
  58. 6.10.3 Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio
  60. 6.10.5 Amprologix Ltd Recent Developments
7 North America by Country
  1. 7.1 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country
  2. 7.1.1 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021-2026)
  4. 7.1.3 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Forecast by Country (2027-2032)
  5. 7.2 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country
  6. 7.2.1 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2021-2026)
  8. 7.2.3 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country
  2. 8.1.1 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021-2026)
  4. 8.1.3 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country
  6. 8.2.1 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2021-2026)
  8. 8.2.3 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country
  2. 9.1.1 Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country
  6. 9.2.1 Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country
  2. 10.1.1 South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021-2026)
  4. 10.1.3 South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Forecast by Country (2027-2032)
  5. 10.2 South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country
  6. 10.2.1 South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2021-2026)
  8. 10.2.3 South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country
  2. 11.1.1 Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country
  6. 11.2.1 Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Value Chain Analysis
  2. 12.1.1 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Production Mode & Process
  7. 12.2 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Distributors
  10. 12.2.3 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst